Table 5.
Intergroup comparison between changes from baseline at 14 day of the study
| Parameters | Placebo (n=29) | NXT15906F6- 250 (n=30) | NXT15906F6- 400 (n=30) | *p value between mean changes | |
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Placebo vs. NXT15906F6- 250 | Placebo vs. NXT15906F6- 400 | |
| Stair climbing time (s) | 0.21±0.82 | -1.75±1.28 | -1.87±0.92 | <0.0001 | <0.0001 |
| Visual analogue scale (VAS) Score | -0.27±0.84 | -1.17±1.10 | -1.40±1.05 | 0.0002 | <0.0001 |
| WOMAC-A (pain) score | -0.86±5.36 | -5.83±6.17 | -5.83±4.56 | 0.0001 | <0.0001 |
| WOMAC-B (Stiffness) score | 0.69±5.30 | -2.17±5.52 | -1.67±4.01 | 0.0069 | 0.0119 |
| WOMAC-C (Physical functioning)scores | -4.14±14.82 | -12.17±16.49 | -11.33±9.09 | 0.0070 | 0.0160 |
| Total WOMAC score | -3.97±19.24 | -20.17±23.83 | -18.83±14.24 | 0.0002 | 0.0005 |
| Primary knee flexion (degrees) | 0.24±0.51 | 0.50±0.90 | 0.67±0.96 | 0.2158 | 0.0351 |
Data presented as mean±SD, *Comparison between mean change from baseline scores in the placebo and mean changes from baseline scores in NXT15906F6 groups at day 14 are analyzed using an ANCOVA model.